Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Bright Minds Biosciences Inc. C.DRUG

Alternate Symbol(s):  DRUG

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

Upcoming catalysts

The next couple of catalysts include the toxicology study for 5HT2A to treat MDD/TRD and the Phase-1 clinical trials for BMB-101 to treat Alzheimer's.  Both are likely to start this quarter  rate and reply

RE:Bright Minds Moves Into Clinical Development Stage Following

That's wonderful. Just waiting for the stock to take off  rate and reply

Bright Minds Moves Into Clinical Development Stage Following

Drug development continues for the Bright Minds Biosciences lead product. The firm this morning published positive results from a recent 28-day toxicity study conducted on its novel formulation, more

BMB-101 is all set to hit the clinic in H1’22

Unlike most biotechs developing drugs from naturally occurring psychedelics, Bright Minds is creating novel compounds that retain the therapeutic benefits of psychedelics while minimising side more


"I would say we have the largest and most advanced psychedelic drug discovery program in the history of the world. That’s over 25 chemists working around the clock developing completely more

BMB: The next-gen psychedelics to treat neuro conditions

Bright Minds has a portfolio of three patented mechanisms based on serotonin (5-HT) receptors, assessed for indications ranging from depression to chronic pain. The firm also has " more

RE:Bright Minds Bioscience Approved For Nasdaq Listing

This is one of the best news for the psychedelic sector in a long time...Way to go BM  rate and reply

Bright Minds Bioscience Approved For Nasdaq Listing

There’s another Canadian firm set to trade on the Nasdaq market. Bright Minds Bioscience this morning announced that it has been approved to begin trading on the major big board exchange. more

Dr Gideon Shapiro's podcast interview with Hogan Mullally

Watch Dr Gideo Shapira, VP of discovery discuss the recent, upcoming events at Bright Minds Biosciences and how the success of other firms like Compass Pathways could positively impact the more

BMB to participate in the LD Investment Conference

Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of more

Ian McDonald's interview with James Hallifax

Watch Ian McDonald, CEO of Bright Minds Biosciences' interview with James Hallifax- Psychedelic Investor YouTube Channel  rate and reply

RE:Bright Minds Biosciences Proprietary Compound Shows Reductio

Bright Minds looks all set to begin clinical trials on their New Chemical Entity (NCE), BMB-101 sometime in Q1 2022. That's gonna be a big relief to patients suffering from Dravet syndrome, more

Bright Minds Biosciences Proprietary Compound Shows Reductio

Bright Minds Biosciences this morning announced preliminary results from an ongoing study being conducted by the firm. The company has seen efficacy in rodent models of Dravet Syndrome, a form more

Ian McDonald & Gideon Shapiro chat with therealbrom

Watch Brom from theintegrationcompany interview Ian McDonald & Gideon Shapiro GingerCannot connect to Ginger Check your internet more

BMB- A Search For GW Pharmaceuticals In The Psilocybin Space

Here's an amazing research report from Colin Sullivan making the case for Bright Minds Biosciences, the market size for their drugs, estimated total free and discounted cash flow, NPV and more

Brom to interview BMB CEO on "The Integration Conversation"

Brom is interviewing Bright Minds CEO Ian McDonald and VP of Discovery Dr. Gideon Shapiro on his podcast, "The Integration Conversation" today. The podcast /youtube channel features more

Paradigm Market Research Inc's top picks

Emerita Resources EMO Bright Minds Biosciences DRUG Deep South Resources DSM Cross River Ventures CRVC For additional info, lookup more


Watch this very informative video to know more about the various serotonin receptors, what causes neurological disorders and how Bright Minds Biosciences (CSE: DRUG, OTCQB: BMBIF) is at the more

DRUG mentioned in Paradigm newsletter

Newsletter  rate and reply

BMBIF Nasdaq uplisting

I'm buying on every decline and hope to have at least 2k shares before they uplist  rate and reply